-
Business
-
Policy & Business
-
-
Federal IT
-
Information Technology
-
-
State & Local
-
State & Local Government
-
-
Defense
-
Defense & Intelligence
-
-
Healthcare
-
Healthcare Policy & IT
-
-
Energy
-
Energy Policy & Technology
-
-
Education
-
Education Policy & Technology
-
FDA advisory panel backs Merck's blood clot-preventing drug
Reuters: Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.
Tags
Share
Top Stories
- CMS watchdog suggests targeted approach for hospital wage index increase
- When PHE Ends, Don't Expect Grace Period From CMS
- Lawmakers left hospital, insurer contract guardrails out of year-end proposal
- CMS creates direct contracting model to serve individuals dually eligible for Medicare and Medicaid
- Local Health Departments Are Understaffed. Would Biden’s ‘Public Health Jobs Corps’ Help?
- HHS wants to boost interoperability for Medicaid and CHIP
- CDC is giving $227 million for COVID-19 vaccine preparedness and tracking
- ‘We want them infected’: Trump appointee demanded ‘herd immunity’ strategy, emails reveal
- CMS Updates Part B Payment Information for COVID-19 Treatments
- FDA finds Moderna vaccine 95% effective
- FDA Analysis Of Pfizer COVID-19 Vaccine Finds It Effective And Safe
- High court will hear appeal over Medicaid work requirements
- Bipartisan Cadre of Lawmakers Call for Permanent Telehealth Expansion
- Biden Will Issue Mask Mandate for Federal Buildings
- CMS unveils highly anticipated geographic direct-contracting model
- Pushed to rush, FDA head says feds will get vaccine 'right'
Whitepapers & Special Reports
i360Gov Newsletters
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe NowAlso in Healthcare Policy & IT
About
i360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Contact Us
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
Newsletters
Copyright © 2009-2025 i360Communications, LLC.